Projects per year
Personal profile
Education
- 1992 Ph.D., (Pharmacy), Taipei Medical University
- 1985 M.S., (Pharmacy), Taipei Medical University
- 1983 B.S., (Pharmacy), Taipei Medical University
Experience
- 2012 Professor,Department of Pharmaceutical Sciences, Taipei Medical University
- 2003-2012 Professor, Collage of Pharmacy, Taipei Medical University
Research Interests
- Pharmaceutical Analysis
- Development of biomaterials in drug delivery system
Fingerprint
Dive into the research topics where Hsiu-O Ho is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Studies on Development of Thermostable Glycosylated Plga Nanoparticles Loaded with Mrna Encoding Sars-Cov-2 Spike Protein as Covid-19 Vaccine
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
發展可標靶樹突細胞之mPEG-PLGA/PLGA-PEG-PLGA混和水膠體的奈米顆粒癌症疫苗用於癌症免疫療法(3/3)
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
發展可標靶樹突細胞之mPEG-PLGA/PLGA-PEG-PLGA混和水膠體的奈米顆粒癌症疫苗用於癌症免疫療法(2/3)
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
-
Development of Cancer Vaccine Nanoparticles Composed of Mpeg-Plga/Plga-Peg-Plga Mixed Hydrogel for Cancer Immunotherapy by Targeting to Dendritic Cells(1/3)
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
-
Development and Optimization for Injectable Thermosensitive Hydrogel-Based Scaffolds with Delivering Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf) in Cancer Immunotherapy
8/1/18 → 7/1/19
Project: A - Government Institution › b - Ministry of Science and Technology
-
Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer
Liu, Y. H., Chen, L. C., Cheng, W. T., Wei, P. S., Hsieh, C. M., Sheu, M. T., Lin, S. Y., Ho, H. O. & Lin, H. L., Feb 2023, In: Pharmaceutics. 15, 2, 473.Research output: Contribution to journal › Article › peer-review
Open Access -
Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy
Cheng, W. J., Chuang, K. H., Lo, Y. J., Chen, M., Chen, Y. J., Roffler, S. R., Ho, H. O., Lin, S. Y. & Sheu, M. T., Apr 2022, In: Journal of Controlled Release. 344, p. 235-248 14 p.Research output: Contribution to journal › Article › peer-review
4 Citations (Scopus) -
Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer
Cheng, W. J., Lin, S. Y., Chuang, K. H., Chen, M., Ho, H. O., Chen, L. C., Hsieh, C. M. & Sheu, M. T., 2022, In: International Journal of Nanomedicine. 17, p. 5353-5374 22 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination
Chou, P. Y., Lin, S. Y., Wu, Y. N., Shen, C. Y., Sheu, M. T. & Ho, H. O., Nov 2022, In: Journal of Controlled Release. 351, p. 970-988 19 p.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus) -
Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity
Cheng, W. J., Lin, S. Y., Chen, M., Chen, L. C., Ho, H. O., Chuang, K. H. & Sheu, M. T., 2021, In: International Journal of Nanomedicine. 16, p. 4017-4030 14 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus)
Datasets
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Chen, L. (Contributor), Lin, S. (Contributor), Sheu, M. (Contributor), Ho, Y. (Contributor), Su, C. (Contributor), Chen, M. (Contributor), Ho, H. (Contributor) & Chuang, K. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.6213620, https://doi.org/10.6084%2Fm9.figshare.6213620
Dataset
-
Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
Chang, C. (Contributor), Hsieh, C. (Contributor), Chen, L. (Contributor), Su, C. (Contributor), Liu, D. (Contributor), Jhan, H. (Contributor), Ho, H. (Contributor) & Sheu, M. (Contributor), Unknown Publisher, Jan 1 2018
DOI: 10.6084/m9.figshare.5908795.v1, https://tandf.figshare.com/articles/Novel_application_of_pluronic_lecithin_organogels_PLOs_for_local_delivery_of_synergistic_combination_of_docetaxel_and_cisplatin_to_improve_therapeutic_efficacy_against_ovarian_cancer/5908795/1
Dataset
-
Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
Hsieh, C. (Contributor), Chen, L. (Contributor), Liu, D. (Contributor), Ho, H. (Contributor), Su, C. (Contributor), Sheu, M. (Contributor), Jhan, H. (Contributor) & Chang, C. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.5908795, https://doi.org/10.6084%2Fm9.figshare.5908795
Dataset
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Su, C. (Contributor), Chen, M. (Contributor), Chen, L. (Contributor), Ho, Y. (Contributor), Ho, H. (Contributor), Lin, S. (Contributor), Chuang, K. (Contributor) & Sheu, M. (Contributor), Unknown Publisher, May 2 2018
DOI: 10.6084/m9.figshare.6213620.v1, https://tandf.figshare.com/articles/Bispecific_antibodies_anti-mPEG_anti-HER2_for_active_tumor_targeting_of_docetaxel_DTX_-loaded_mPEGylated_nanocarriers_to_enhance_the_chemotherapeutic_efficacy_of_HER2-overexpressing_tumors/6213620/1
Dataset